Io Therapeutics, Inc.
Records under this name other than the patents Io Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 52 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,034,845 | Autoimmune disorder treatment using RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,201,512 | Autoimmune disorder treatment using RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,285,960 | Autoimmune Disorder Treatment using RXR Agonists Formerly held In force · Low confidence | In force | Low confidence | |
| US 11,166,927 | Autoimmune disorder treatment using RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,246,845 | Autoimmune disorder treatment using RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,793,781 | Autoimmune disorder treatment using RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,547,684 | Autoimmune disorder treatment using RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,383,521 | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,653,650 | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,940,127 | Use of CYP26-Resistant Rar Alpha Selective Agonists in the Treatment of Cancer Formerly held In force · High confidence | In force | High confidence |